Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gollust SE, Saloner B, Hest R, Blewett LA. US Adults’ Preferences for Public Allocation of a Vaccine for Coronavirus Disease 2019. JAMA Netw Open. 2020;3(9):e2023020. doi:10.1001/jamanetworkopen.2020.23020
A vaccine against severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) will be essential for mitigating the pandemic. However, given global need, demand is expected to exceed supply. When vaccines were limited during the 2009 H1N1 pandemic, the Centers for Disease Control and Prevention developed recommended priority populations based on ethical criteria.1 Experts have begun to identify which groups ought to receive priority for a SARS-CoV-2 vaccine, including elderly people, front-line health care workers, and people with existing medical conditions that put them at high risk of severe illness and death.2-4
Public engagement can contribute to resource allocation decisions. Incorporating public preferences could advance the perceived legitimacy of vaccine allocation guidelines.4 This survey study’s objective is to describe the public’s preferences for allocating a SARS-CoV-2 vaccine.
Create a personal account or sign in to: